Gilead Sciences Inc. (NASDAQ: GILD) is a global biopharmaceutical company advancing treatments in antiviral, oncology, and inflammatory diseases. Known for breakthroughs in HIV and hepatitis therapies, it continues expanding its pipeline into oncology and cell therapy. Gilead’s stock performance is driven by clinical results, drug pricing dynamics, and growth in its oncology and antiviral franchises.